Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-2. (cancelled)
- 3. (Original) A pharmaceutical composition for the treatment of deep vein thrombosis comprising a nucleic acid ligand to a β_3 integrin and a pharmaceutically acceptable excipient.
- 4. (Original) A method for detecting a deep vein thrombosis in an individual, the method comprising:
 - (a) providing a nucleic acid ligand to a β_3 integrin, said nucleic acid ligand conjugated to a radioactive label;
 - (b) administering said nucleic acid ligand to said individual;
 - (c) detecting the site of said thrombosis by analyzing the localization of said nucleic acid ligand using a radioimaging technique.
- 5. (Original) An anti-clotting composition for use in acute coronary syndromes and percutaneous coronary intervention, the composition comprising a nucleic acid ligand to a β_3 integrin and a pharmaceutically-acceptable excipient.
 - 6-7. (cancelled)